I was born on 6 August 1956 in San Francisco, California to Janet and (the late) Richard Hovis.
I grew up in Santa Monica, California where I attended elementary, junior high school, and high school (graduating in 1974), in addition to involvement in sports and recreation (Little League +, the Boy’s Club ++). Further, it was in elementary school – St. Augustine’s By-the -Sea Parish School that I found, and made the choice to truly journey with God.
I attended Arizona State University from 1974 to 1977 – seeking to become an architect, however, I was not accepted, and, as such, I graduated with a Liberal Arts degree.
Upon graduation from Arizona State University, I attended Cal Poly San Luis Obispo and studied City and Regional Planning at the Master’s level. I successfully completed one (1) year in a two (2) year program – I did not complete the Master’s degree in City and Regional Planning – due to personal reasons.
I returned to Santa Monica where I started (October 1979) my career as graphic designer with Exxon Company, USA. I spent five years with Exxon Company, USA.
While working with Exxon Company, USA I was accepted into architectural school – Sci-Arc in Southern California, however, I did not attend preferring to stay with Exxon..
In 1982 I married Laura Flosi and in April 1983 we had our one and only child – Lauren Alain Hovis – a gift from God.
We moved to Phoenix, Arizona in 1984 from Los Angeles, where I went to work as a graphic designer with Kitchell CEM (from 1985 -1987).
From 1987 – 1995 I was an independent contractor, and a registered representative in mortgage finance, financial management, graphic design, and drafting.
Further, I attended the University of Phoenix and successfully obtained a Master’s in Business Administration (MBA) in 1982.
I was also a member of the Scottsdale Jaycees, where I became very involved in community events and projects.
In 1994, I accepted a cartography position with the Defense Mapping Agency in Reston, Virginia. As such, I relocated from Phoenix to Reston.
In 1998, I was accepted and worked as a Visual Information Officer with the Central Intelligence Agency. In 2002, I worked as a Support Officer until my retirement (due to a need for shoulder surgery) in September 2018.
Away from my Federal Government service, I have been involved in various organizations and activities in Northern Virginia.
In November of 2011, I married Rebecca Ouellette in Santa Monica, California. I reside in San Tan Valley, AZ with my two hamster - Jess and Timothy, our fish, our lizard - RJ Lizard., and our cats - Pearl and Grey.
As to hobbies, I enjoy playing sports, attending sporting events, mentoring individuals from financial management to hamsters, building models, photography, travel, multimedia design, managing partner for RJ Hamster, and jazz – smooth jazz to a samba or a bossa nova.
Love and God Bless,
Peter – aka RJ Hamster Jo hi
Dehydration is an ancient art, but it has to be done correctly.
If you get the temperature wrong, or if you slice the meat too thick, you risk something called “Case Hardening.”
This is when the outside of the food dries too fast, trapping moisture inside. To the naked eye, it looks dry. But inside? Mold and bacteria are growing.
Don’t risk your family’s health.
I wrote “The No-Fridge Survival Cookbook” to give you the exact safety protocols for dehydrating meat, poultry, and vegetables.
I want to send you a physical copy for free.
In Chapter 2, I cover:
The Kill Step: Why poultry must hit 165°F before or after drying.
Prague Powder #1: When you absolutely MUST use curing salt (and when you can skip it).
The Conditioning Jar: The simple 7-day test that guarantees your food won’t mold.
Knowledge is safety. Before you run another cycle on your dehydrator, get this book.
In the vast landscape of news and media, it’s essential that we don’t let important conservative stories slip through the cracks. Our mission is to provide comprehensive coverage that champions our shared values.
Did we overlook a story or event that you believe deserves attention?
👉 Hit ‘Reply’ and let us know. Your insights ensure that our community remains informed and that every conservative voice gets the platform it deserves.
Together, we can ensure that no story goes untold and that our conservative principles are represented in every conversation.
Thank you for being an active participant in our mission.
Material Connection Disclosure: Unless otherwise expressly stated, you should assume that all references to products and services on this website are made because material connections exist between the sender of this email and the providers of the mentioned products and services.Anti Spam PolicyPrivacy PolicyTerms of UseCompensation Disclosure
Patriot Powered Publishing | 5613 SE 67th St OK 73135
The following may contain promotional content from our paid sponsors.
Dehydration is an ancient art, but it has to be done correctly.
If you get the temperature wrong, or if you slice the meat too thick, you risk something called “Case Hardening.”
This is when the outside of the food dries too fast, trapping moisture inside. To the naked eye, it looks dry. But inside? Mold and bacteria are growing.
Don’t risk your family’s health.
I wrote “The No-Fridge Survival Cookbook” to give you the exact safety protocols for dehydrating meat, poultry, and vegetables.
I want to send you a physical copy for free.
In Chapter 2, I cover:
The Kill Step: Why poultry must hit 165°F before or after drying.
Prague Powder #1: When you absolutely MUST use curing salt (and when you can skip it).
The Conditioning Jar: The simple 7-day test that guarantees your food won’t mold.
Knowledge is safety. Before you run another cycle on your dehydrator, get this book.
In the vast landscape of news and media, it’s essential that we don’t let important conservative stories slip through the cracks. Our mission is to provide comprehensive coverage that champions our shared values.
Did we overlook a story or event that you believe deserves attention?
👉 Hit ‘Reply’ and let us know. Your insights ensure that our community remains informed and that every conservative voice gets the platform it deserves.
Together, we can ensure that no story goes untold and that our conservative principles are represented in every conversation.
Thank you for being an active participant in our mission.
Material Connection Disclosure: Unless otherwise expressly stated, you should assume that all references to products and services on this website are made because material connections exist between the sender of this email and the providers of the mentioned products and services.Anti Spam PolicyPrivacy PolicyTerms of UseCompensation Disclosure
Patriot Powered Publishing | 5613 SE 67th St OK 73135
Why Are Chronic Diseases Skyrocketing? The Hidden Culprit Behind America’s Health Crisis
Dear Reader,
Despite remarkable advancements in medical science, chronic diseases like heart disease, cancer, diabetes, and Alzheimer’s continue to skyrocket. So, what’s the real cause behind this alarming trend?
The answer is a stealthy villain that’s been quietly damaging our health for years: chronic inflammation.
A Vital Warning From Dr. Russell Blaylock, M.D.
Dr. Russell Blaylock, a world-renowned neurosurgeon and leading health expert, is exposing the shocking truth behind inflammation’s destructive role in some of today’s most deadly diseases. Fueled by common foods, hidden toxins, and environmental factors, inflammation is silently wreaking havoc on your body — leading to debilitating and life-threatening conditions.
Why You Should Be Alarmed
Heart Disease: Over 800,000 deaths annually in the U.S.
Cancer: 1.96 million new cases every year.
Diabetes: 37 million current cases, with millions more at risk.
Alzheimer’s, Obesity, Arthritis, and More: All linked to chronic inflammation.
Despite breakthroughs and billion-dollar medications, people are still getting sicker. The underlying cause? Inflammatory sugars, harmful oils, chemicals, and GMOs hiding in everyday foods are keeping us ill.
But There’s a Solution!
Dr. Blaylock has developed an Anti-Inflammation Program packed with proven strategies to stop, reverse, and prevent inflammation — empowering you to live healthier and avoid these devastating diseases. With his program, you’ll discover how to:
Easily spot and eliminate disease-causing foods.
Add nutrient-rich, anti-inflammatory ingredients to your diet.
Make simple adjustments that deliver lasting, life-changing health benefits.
Exclusive Free Offer — Get Healthy Today
For a limited time, you can access Dr. Blaylock’s complete Anti-Inflammation Program — a $140 value — for FREE! This includes critical reports on reversing inflammation, debunking harmful medical myths, and preventing diseases naturally.
CLAIM YOUR FREE HEALTH KIT NOW! Click Here to reverse inflammation and protect your body from deadly diseases!
LAST CHANCE: Get Your $140 Anti-Inflammation Kit FREE
This email is never sent unsolicited. You have received this Newsmax email because you subscribed to it or someone forwarded it to you. To opt out, see the links below.
Remove your email address from our list or modifyyour profile. We respect your right to privacy. Viewour policy.
This email was sent by: Newsmax.com 362 N. Haverhill Road West Palm Beach, FL 33415 USA
This free masterclass is a unique opportunity to get FREE trade ideas and perspectives from both a member of the Options Trading Hall of Fame and every day trader who grew his wealth from his home office.
It starts on Wednesday, Jan. 28 at 2 p.m. ETin the MTALive chatroom.
Between the Greenland situation and the WEF meeting, I was feeling decision fatigue on Friday.
As a trader, when mental power starts slowing down, you have to keep your wits.
Patience becomes key.
And one of the lotto setups I was waiting on was Carvana (CVNA).
The chart looked incredible.
It was nearing all-time highs at $485 with an A+ squeeze.
Given this momentum potential, I took out a lotto trade and 1 butterfly trade targeting $500 on Thursday.
I paid .39 for this butterfly trade on CVNA.
By the end of the trading day, it was closing at $2.13.
So I closed the first lotto for a 400% gain, but I wasn’t done yet.
Although the lotto was closed, I held on to the butterfly trade for a few reasons…
One, I thought CVNA had more room to run.
Two, given that CVNA options were super cheap the next day, I could capture that continued momentum without as much risk.
All I needed was a little push into all-time highs.
So I added to the lotto on Friday.
Then in less than 1 hour, that momentum shift came.
CVNA moved up into all-time highs, and I closed the lotto trade for a 370% winner.
All together – we captured nearly a 1000% gain on CVNA – all in less than 2 trading days.
Freaking awesome.
That’s the power of using patience and building on a lotto trade for a massive gain.
The one thing I caution traders is once you capture that massive gain – there’s a temptation to get back in on a quick dip and try to ride it for more.
Don’t do it.
I can’t tell you the number of times I’ve made a big gain on an options trade only to give it all back by thinking it’ll keep going higher.
Once I get the move into all-time highs, I close the trade and avoid trading that name for the rest of the day (usually).
Here’s what a few Daily Profits Live members had to say about the trade.
Carvana has the potential to keep running, so I’ll be looking to position via spreads in this week and next week in Daily Profits Live.
SPONSORED
Elon Musk’s Final Project REVEALED
It’s a secret project … bigger than Tesla … bigger than SpaceX … and bigger than Twitter.
You are receiving this email because you subscribed to Trade of the Day Wake-Up Watchlist. To unsubscribe from Trade of the Day Wake-Up Watchlist, click here.
Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox.
To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201
Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation.
Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.
Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.
(TLSA) Comes Backed By 7 Potential Catalysts (See Below)
Full Coverage Will Be Starting Very Shortly
Take A Close Look At (TLSA) While It’s Still Early…
January 26, 2026
First Look | See Why (TLSA) Just Jumped On To Our Early Morning Watchlist
Dear Reader,
The landscape of neurological medicine is shifting as a single biotech firm advances a delivery method that could change how we address some of the most stubborn diseases of the human brain.
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is currently at the center of this transition, utilizing a unique intranasal approach to treat neurodegenerative conditions that have long lacked effective solutions.
With a recent peer-reviewed publication and a surge in institutional support, this company is demanding the attention of anyone monitoring the future of biotechnology.
And that’s just some of the reasons why (TLSA) is topping our watchlist this morning—Monday, January 26, 2026.
Even at this early stage, (TLSA) is starting to stand out as one of the more closely followed names in neuro-immunology, thanks to a delivery approach that directly addresses the central nervous system.
And now, outside observers are beginning to put hard numbers around what that progress could mean.
Analyst Target Suggests Over 400% Upside Potential
One analyst has begun to take note of the progress at Tiziana Life Sciences, Ltd. (Nasdaq: TLSA).
Recently, Elemer Piros, PhD, an analyst withLucid Capital Markets, published a bullish rating on the company. Dr. Piros set an $8 target on (TLSA), which suggests a 406% potential upside from its recent price range of $1.58.
This valuation is largely driven by the potential of the Foralumab platform and its applicability across a potential $33B market.
The analyst community often looks forde-risking events, and the recent peer-reviewed data for SPMS is considered a major milestone. As the company moves toward Phase 2 results in both MS and Alzheimer’s, the potential for upward revisions in valuation remains high, especially if thesafety profile continues to hold up in larger patient populations.
The Tiziana Approach to Neuro-Immunology
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is a clinical-stage biotechnology company headquartered in London and New York, dedicated to developingtransformative therapies that leverage the body’s own immune system. The company’s primary focus revolves around its proprietary platform for theintranasal delivery of monoclonal antibodies.
Unlike traditional intravenous methods, thisnasal-to-brain route is designed to bypass the blood-brain barrier, potentially allowing for localized therapeutic effects in the central nervous system while minimizing systemic side effects.
The company operates in the high-stakesneuroscience market, specifically targeting Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer’s disease, and Amyotrophic Lateral Sclerosis (ALS).
What makes (TLSA) distinctive is its lead candidate,Foralumab, which is the only entirely human anti-CD3 monoclonal antibody in clinical development.
By modulating T-cell responses and reducing neuroinflammation, (TLSA) aims to provide a new standard of care for patients who have exhausted traditional options.
Founded in 1998, the company has spent decades refining its approach toimmunotherapy. Its lean and virtual research model allows it to focus capital on high-value clinical activities rather than heavy overhead. This strategic structure has enabled TLSA to maintain a robustpipeline while advancing multiple orphan and large-market indications simultaneously.
The Scientific Foundation: Intranasal Foralumab
At the heart of Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is the scientific conviction that neuroinflammation is a primary driver of disease progression in the brain.Foralumab works by binding to the T-cell receptor complex, specifically the CD3 epsilon subunit. When administered through the nasal cavity, the therapy is designed to stimulateregulatory T cells (Tregs) in the cervical lymph nodes.
These “calming” cells then migrate to the brain, where they work to dampen the activity ofmicroglia—the immune cells of the central nervous system that, when overactive, cause tissue damage in MS and Alzheimer’s patients.
Thismechanism of action is a radical departure from traditional treatments. Most current MS therapies focus on systemic immunosuppression, which can leave patients vulnerable to infections.
In contrast, (TLSA) focuses onlocal modulation. By harnessing the body’s natural regulatory pathways, the company hopes to restorehomeostasis in the brain without compromising the rest of the immune system.
Clinical Momentum and Market Positioning
The core thesis for Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) rests on its recentclinical validation and its unique position in the neuro-immunology sector.
On January 20, 2026, the company announced thepeer-reviewed publicationof clinical study results for intranasal Foralumab, which showed signs of stabilizing disease progression and reducing microglial activation in patients with na-SPMS.
This publication in a respected medical journal provides a layer ofscientific credibility that is essential for biotechnology firms approaching late-stage trials.
Targeting Massive Unmet Needs
The market potential for (TLSA) is substantial, as the globalMultiple Sclerosis market is projected to be worth approximately $16.8B in 2026. Specifically, the non-active Secondary Progressive Multiple Sclerosis (na-SPMS) population represents asignificant segment of patients—estimated at roughly 30% to 40% of all MS cases—who currently have no FDA-approved treatments.
By positioning Foralumab as a potential first-in-class therapy for this group, (TLSA) is entering an area with minimal direct competition and high demand.
The company is also moving aggressively into Alzheimer’s disease, having already dosed the first patient in a Phase 2 trial.
With the global Alzheimer’s market projected togrow over 300% from around $7.7B in 2026 to over $33.6B by 2034, a successful inflammation-based therapy could represent a massive therapeutic class.
Unlike treatments focused strictly on amyloid plaque removal, TLSA is targeting theneuroinflammation that often persists even after plaques are cleared.
This rapid market expansion, driven by a global aging population, suggests that even a small share of the Alzheimer’s market could be transformative for a clinical-stage firm.
Strengthened Financial and Leadership Support
Operational achievements have been matched by a bolsteredbalance sheet. In January 2026, (TLSA) closed an oversubscribed $8.8M registered direct offering, following a previous announcement of an offering up to $17.6M. This capital infusion is intended to fund the continued Phase 2a clinical trial of Foralumab.
Furthermore, theExecutive Chairmanrecently increased his personal stake in the company, signaling strong internal confidence in the firm’s trajectory.
The company currently maintains a market capitalization of approximately $174M, with recent analyst notes highlighting that the current valuation may not fully reflect the potential of itsmulti-indication pipeline. With recent funding secured, (TLSA) has extended its runway to meet several high-impact data readouts expected throughout 2026.
Expert Management and Strategic Presence
Themanagement team at TLSA consists of seasoned veterans from major pharmaceutical backgrounds. Executive ChairmanGabriele Cerrone has a history of founding and scaling successful biotech ventures, including companies later acquired by major players like Bristol Myers Squibb.
This level of experience is vital for navigating the complex regulatory and commercial hurdles of theFDA approval process.
Their presence was felt during the9th Annual Neuroscience Innovation Forumheld during the J.P. Morgan Healthcare Conference week in San Francisco. This platform allowed the company to showcase itspipeline to global institutional observers and potential strategic partners. Engaging with the broaderbiotech community at such a critical venue underscores the company’s commitment to transparency and clinical progress.
Beyond MS: A Versatile Pipeline
While MS and Alzheimer’s are the leading programs, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is developing a platform, not just a single application. The company has clinical assets targetingALS, a devastating condition with few viable treatments. Preclinical data suggests that the sameTreg stimulation seen in MS could help slow the motor neuron degradation characteristic of ALS.
Additionally, the company owns rights toMilciclib (TZLS-201), an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs). Milciclib has already shownsafety and tolerability in over 300 patients across Phase 1 and 2 trials for advanced solid cancers. By maintaining a diversified portfolio that includes bothoncology and neurodegenerative programs, (TLSA) mitigates the risk inherent in single-program biotech firms.
The company’sTZLS-501 program also explores the use of anti-interleukin-6 receptor (anti-IL6R) monoclonal antibodies. This asset is being explored for its potential to treat lung inflammation, demonstrating the breadth of the company’sintellectual property portfolio. The ability to pivot this technology to various inflammatory sites makes (TLSA)a versatile player in the immunotherapy space.
7 Reasons Why (TLSA) is Topping Our Watchlist This Morning
—Monday, January 26, 2026…
1. Analyst Target: With an $8 targetfrom Lucid Capital Markets, (TLSA) is framed as having over 400% upside potential based on its recent range.
2. Chart History: Around this time last year, (TLSA) showed sharp volatility with an approximate 300% move in under 6 months, from around $0.65 to $2.60.
3. Peer Validation: A recent peer-reviewed publication of intranasal Foralumab results gives (TLSA)independent scientific support for its core approach.
4. Oversubscribed Funding: Anoversubscribed $8.8M registered direct offering in January 2026 provides (TLSA)added liquidity to pursue upcoming clinical milestones.
5. Insider Confidence: A recent increase in the Executive Chairman’s personal stake signals internal confidence at (TLSA) from someone closest to the program.
6. Clinical Momentum: Movement toward Phase 2 results in MS and Alzheimer’s keeps (TLSA) positioned around multiple 2026 data readouts tied to markets cited as roughly $16.8B for MS and about $33B for Alzheimer’s.
7. High-Profile Visibility: Participation during J.P. Morgan Healthcare Conference week in San Francisco helped place (TLSA) in front of institutional observers and potential partners.
Take A Close Look At (TLSA) While It’s Still Early…
When you put the pieces together, (TLSA) checks several boxes that serious market watchers tend to prioritize: an analyst target that suggests over 400% upside potential, a demonstrated history of sharp swings, and a peer-reviewed publication supporting its intranasal Foralumab results.
Add in fresh capital from an oversubscribed $8.8M raise, an Executive Chairman increasing his personal stake, and ongoing Phase 2 momentum in both MS and Alzheimer’s—and you can see why attention is building.
The fact that (TLSA) also showed up during J.P. Morgan Healthcare Conference week only reinforces that it’s on more radar screens than it was before.
We have all eyes on (TLSA) this morning.
Take a close look at (TLSA) while it’s still early.
Also, keep a lookout for my next update, it could be on its way to you before the bell rings.
Sincerely,
Gary Silver Managing Editor, Market Crux
MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, MC is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 01/25/2026 and ending on 01/26/2026 to publicly disseminate information about (TLSA:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid twenty one thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Headline Media LLC, TD Media LLC and their member own shares of (TLSA:US).
“We’ve been consuming this ultra-processed food, which I call human pet food,” says Dr. Shawn Baker. A former orthopedic surgeon and world champion athlete, he’s the author of “The Carnivore Diet” and co-founder of the online clinic Revero.
Our mailing address is: The Epoch Times. 229 W. 28 St. Fl. 7 New York, NY 10001 | Contact Us
The Audio Room newsletter is one of the best ways to receive the most up-to-date information. Manage your email preferences here or unsubscribe from The Audio Room her
Trump’s $500 Billion Artificial Intelligence Infrastructure Initiative Could Drive These 5 Stocks Higher
Dear Reader,
It’s the end of the first calendar year of President Trump’s second term, and the results are clear. Markets are at record highs, and investors are pouring capital into the sectors most favored by his administration’s economic agenda.
At the center of this growth is Trump’s $500 billion artificial intelligence infrastructure initiative, a cornerstone policy driving major gains across banking, energy, and defense.
Our analysts have identified five companies best positioned to benefit from these developments. You’ll find them in our free report, 5 Best Stocks to Buy Under the Current Administration.
Inside, you’ll see:
A banking powerhouse expanding as deregulation deepens
An energy leader increasing production at record levels
A defense contractor capturing new federal spending
An immigration services firm gaining from border policy changes
A media company growing with the “Patriot Economy”
If you missed the early rally, this second phase of Trump’s economic resurgence could be your next opportunity.
Get your complimentary copy now before the next policy announcement moves these stocks again.
Download The 5 Best Stocks to Buy Under the Current Administration Report
By clicking ‘Download the Report’ you will subscribe to Wealth Creation Investing and will also receive a free subscription to Monument Traders Alliance
StartEngine is aiming to lead that shift. The platform has seen $1.5B invested from a community of 2.1M+,² including investments in offerings for exposure to pre-IPO companies like Databricks and Groq.³
Now StartEngine is preparing to close its own funding round after its strongest year ever, with $92M revenue YTD in 2025 and EBITDA-positive every quarter.⁴
This is a paid advertisement for StartEngine’s Regulation A+ Offering and is not a recommendation or offer to buy or sell securities. The advertiser, Strikepoint, acting on behalf of StartEngine Crowdfunding, Inc., has paid Darwin Investor Network $6,000 to distribute this advertisement across email and media channels. Neither the advertiser nor Darwin Investor Network owns, or has any agreement to receive, shares or other securities of StartEngine Crowdfunding in connection with this promotion. This compensation creates a conflict of interest, as Darwin is incentivized to promote this offering.
Darwin Investor Network is not registered or licensed as a financial advisor, broker-dealer, or investment professional. We do not provide financial, investment, or trading advice. The information contained herein is based on publicly available sources but has not been independently verified. Investors should not rely on this information without conducting their own independent due diligence.
Investing in small-cap, microcap, or early-stage companies involves significant risk, including the possible loss of your entire investment. These securities may be illiquid and subject to significant price volatility. Past performance is not indicative of future results.
The promoted company, its affiliates, or third-party shareholders may sell shares during or after this promotion, which could negatively affect the price of securities. Companies featured in investor awareness campaigns may experience substantial fluctuations in price and volume.
Offering Disclosures (Provided by StartEngine):
This Reg A+ offering is made available through StartEngine Crowdfunding, Inc. No broker-dealer or intermediary involved in offering. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information, please see the most recentOffering CircularandRisksrelated to this offering, as well as theSupplementto the Offering Circular announcing the “Termination Date.” In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
Note: This information is provided for industry context only and does not imply that StartEngine will achieve similar results, enter into comparable transactions, or secure an acquisition or partnership. Investing in early-stage companies carries risks, with no guarantee of liquidity or future returns.
2. Count determined as number of unique email addresses in StartEngine’s database as of 04-03-2025. One individual may have more than one email address. In May 2023, StartEngine acquired assets of SeedInvest, including email lists for SeedInvest’s users, investors and founders. Click here for more details. Amount invested includes $470M in funds raised previously through offerings conducted on www.seedinvest.comoutside of the StartEngine platform.
3. The underlying companies held by StartEngine Private Funds LLC, and StartEngine Private LLC (together, “StartEngine Private”) are not participating or involved in the offering. The availability of company information does not indicate that the company has endorsed, supports or otherwise participates with StartEngine Private or any of its affiliates. StartEngine Crowdfunding LLC purchases shares from current and former employees, early investors, and advisors of the companies and sells the shares to StartEngine Private for each offering. When you make an investment in a company on StartEngine Private, you are purchasing an interest in a series of StartEngine Private Funds LLC or StartEngine Private LLC, each a Delaware limited liability company (together the “Series LLCs”), which were created to hold shares of privately held companies. An investor will not directly own or hold shares of the private company but instead will own member interests in a series of the Series LLCs, which either directly or indirectly, will hold shares in the company. There may not be a one-to-one economic parity on the value of the Series LLCs interests and the underlying shares.
4. Based on our Q3 2025 Form 10-Q/A. This revenue growth has been driven by StartEngine Private, a new product line that offers funds in late stage companies. This product line has driven over $75.9 million of the $92.7 million in revenue from the first 9 months of 2025. To understand the impact on margins, see financials. Past performance may not be indicative of future performance.
We define Adjusted EBITDA as net income (loss) calculated in accordance with GAAP adjusted to exclude interest expense, interest income, income taxes, depreciation, and amortization, and stock-based compensation. We present Adjusted EBITDA because it is a key measure used by our management team to evaluate our operating performance, generate future operating plans and make strategic decisions. We believe Adjusted EBITDA provides useful information to investors regarding our operational performance and our ability to generate cash flows. Non-GAAP information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, our non-GAAP financial measures may not be the same as or comparable to similar non-GAAP financial measures presented by other companies.
Please see the table on page 36 of our Q3 2025 Form 10-Q/A. This reconciles net income (loss), the most directly comparable U.S. GAAP measure, to Adjusted EBITDA for the periods presented.
5. Bonus shares in this offering are stackable. The maximum amount of bonus shares that an investor can receive is 20%. Any investor who falls into two of the three categories above will receive 20% bonus shares, as will anyone who falls into all three categories.
For example, if an investor reserved shares in StartEngine and is a Venture Club member, they will receive 20% additional shares. If that person also invests over $30,000, they will still receive the maximum of 20% bonus shares. Bonus shares may not immediately appear on your investor dashboard, but will be issued prior to the offering closing.
In order to receive perks from an investment, one must submit a single investment that meets the minimum perk requirement.
If you are investing via a self-directed IRA, you cannot receive additional perks beyond bonus shares due to tax laws.Advertising Disclosure: This email contains paid advertisements. This email is from our associates at StartEngine.
Legal Entity Information: Investing Ideas Daily is owned and operated by Darwin Investor Network, a DBA of The Darwin Agency, Inc.
Disclaimer: Nothing in this email should be considered personalized financial advice. Always conduct your own due diligence when investing. We urge you to read our full disclaimer by clicking on the terms of use link below.
Unsubscribe: You are receiving this email as part of your complimentary subscription to the Investing Ideas Daily E-Letter. If you would like to unsubscribe, you can do so by clicking on the unsubscribe link below.Darwin Investor Network 2319 N Andrews Avenue, Fort Lauderdale, FL 33311 support@investingideasdaily.com | 1-800-496-9838Investing Ideas Daily | Privacy Policy | Terms of Use Unsubscribe | View Online
Small Cap Spike: Semi Stock AEHR Up +40% in 2026 Post-Earnings
Written by Leo Miller on January 21, 2026
Key Takeaways
Aehr Test Systems has soared in the first weeks of 2026, with the catalyst being the firm’s latest earnings.
While the EV market puts pressure on sales, the company is seeing strong momentum in AI-driven demand.
Aehr’s opportunity is large, but uncertainty and a high valuation still cloud the stock’s outlook.
For shares of Aehr Test Systems (NASDAQ: AEHR), it’s hard to imagine a hotter start to 2026. As of the Jan. 20 close, the stock is already up 44% on the year.
The most recent earnings release on Jan. 8 provided mixed signals, but ultimately helped the stock shoot up 16% the next day. With revenues falling, but millions in new artificial intelligence (AI) orders coming in, what does the future hold for the semiconductor stock?
President Trump just approved two long-stalled mining projects tied to strategic U.S. minerals — including silver, which recently broke $68 after soaring 129% last year.
So why should you care?
Because silver isn’t acting like a traditional metal anymore. It’s become essential for AI, energy, and defense… and demand is climbing faster than U.S. supply can keep up. When that happens, prices don’t rise slowly — they can reprice overnight.>> See why this matters for your savings
AEHR’s Earnings: Revenues Plummet, But Booking Projections Come in Strong
On Jan. 8, Aehr reported its Q2 fiscal 2026 (FY2026) earnings. (Note that Aehr’s fiscal reporting period is ahead of the calendar period.) The results painted a mixed picture. The firm recorded revenue of $9.9 million, down 27% year-over-year (YOY) and significantly below the $11.5 million analysts had forecast.
However, Aehr’s adjusted loss per share (EPS) was significantly better than expected, coming in at a loss of 4 cents versus an estimated loss of 8 cents.
The company’s adjusted net loss was $1.3 million, compared with a net income of about $700,000 last year. Notably, the company’s effective backlog increased from $17.5 million in the prior quarter to $18.3 million.
Despite negative earnings news, Aehr’s management provided guidance that was a bright spot in the report.
Over the next two quarters combined, Aehr expects revenue of $25 million to $30 million. This compares to the $32.3 million in revenue Aehr generated in the back half of its fiscal 2025. Aehr also projects bookings of $60 million to $80 million during this period. These bookings can then translate into significant revenue during fiscal 2027.
Bookings coming through and translating into revenue in FY2027 would put Aehr solidly back in growth mode. Based on the company’s guidance, total revenue in FY2026 will be between $46 million and $51 million. The expectation that Aehr’s business will begin to recover stems from its growing presence in the artificial intelligence (AI) market.
AI-Optimism Fuels AEHR as SiC Takes a Backseat
Aehr also said on Jan. 8 that it received over $5.5 million in additional orders for its Sonoma systems. Aehr notes that these orders came from multiple “leading-edge AI companies.” Sonoma demand is accelerating—less than halfway through its fiscal Q3, the company has already received more orders than in all of fiscal Q2.
While Sonoma and AI-driven demand are key growth drivers for Aehr, it is important to understand why the company’s revenue is still declining steeply despite these drivers.
Previously, Aehr saw significant demand from the electric vehicle market. Customers used its FOX-P family of products to stress-test power chips based on silicon carbide (SiC), resulting in strong revenue growth from 2021 to 2023.
SiC-based devices provide substantial benefits over EV power chip technologies that currently dominate the market. This includes the ability to extend EV range by 5% to 10%and cut charging time in half. Aehr believesthat most, if not all, EV companies will move toward SiC-based technology in the future.
However, slowing growth in the EV markethas hurt SiC demand more recently. As SiC demand was previously the company’s largest revenue driver, and AI-driven revenue is still small in comparison, Aehr’s overall sales are dropping.
Pursuant to this, Aehr says that the bulk of its expected bookings are AI-driven, while attributing “not very much at all” of them to SiC. Furthermore, Aehr believes that initial AI customers will expand their orders meaningfully during 2027 and 2028. The company estimates that the AI test-and-burn-in market is between $8 billion and $10 billion today and could reach $15 billion. Clearly, Aehr’s revenues and potential bookings are very small in comparison, providing a large growth opportunity.
Gold Above $5,000 per Ounce in 2026! Here’s How to Play It…
With so many strange events happening across the economy (consumer confidence plummeting, credit-card delinquencies soaring, and more), it’s no wonder the richest investors are loading up on gold. But what you might not realize is that there’s a much better way to profit from rising gold prices – WITHOUT ever touching an ETF, mining stock, or even bullion.Get the full details here.
AEHR: AI-Upside Is Real for This Unproven Player
Aehr’s outlook shifted in a significantly positive direction after its latest financial updates. Still, based on FY2027 estimates, the stock trades at more than 12 times its forward sales. That is not a cheap figure.
However, further momentum in the company’s AI business over the next several quarters could lead to a significant increase in sales estimates. But there is no guarantee that this will materialize, or that Aehr will meet expectations that are already set. Aehr continues to be a stock with strong upside potential, but also prevalent risks.
Investors enter a packed earnings week with markets holding near key technical levels. While the S&P 500 remains rangebound, the Russell 2000 has emerged as a leader—breaking to new highs in recent sessions and setting the tone for small-cap outperformance. The pattern suggests a shift in risk appetite, but the broader trend remains cautious ahead of key catalysts.
Steel Dynamics kicked off the week with Monday morning’s earnings report, offering early insight into the industrial economy. It’s just the beginning—other major reports from UnitedHealth, UPS, Whirlpool, and Tractor Supply are still to come. These names will provide updates across healthcare, logistics, manufacturing, and retail, helping investors gauge the strength and breadth of the economic recovery.
On the macro front, all eyes are on the Fed. Wednesday’s FOMC meeting won’t likely bring a rate cut, but investors will be watching closely for any change in tone. With inflation still above target and labor markets holding steady, the Fed has reason to stay cautious. Last week’s mixed data—solid jobless claims, stable GDP trends, and modest inflation readings—offered little urgency for a policy shift.
Markets aren’t in crisis mode, but momentum is fragile. Many companies are guiding cautiously for Q1, though full-year outlooks remain largely intact. With earnings season accelerating and the Fed set to weigh in, this week could shape sentiment well into February.
Healthcare stocks rallied in 2025, breaking a two-year slump as investors chased steadier rates, better valuations, and improving earnings. The problem: mid-single-digit gains still lagged tech, leaving the sector feeling like a missed opportunity. For investors still hunting for healthcare growt…READ THE FULL STORY
Gold and silver prices are climbing. Global tensions are back in the headlines. Markets are reacting fast. In moments like this, experienced investors don’t trade more, they simplify. A new report breaks down 10 U.S. stocks you can buy and hold with confidence, businesses positioned to benefit from AI, cloud computing, healthcare, and long-term demand. This isn’t a hype list. It’s a long-term playbook designed for uncertain markets, including how to think about allocation when volatility spikes.ACCESS THE FREE 10-STOCK REPORT BEFORE AVAILABILITY CLOSES.
Procter & Gamble (NYSE: PG) confirmed a bottom in early 2026, with its stock price set to advance significantly over the coming years. Trading at long-term lows, the market had priced in the worst-case scenario: tepid growth. However, tepid growth is enough to sustain the company’s fi…READ THE FULL STORY
For companies that have recently returned to the public markets, the first major acquisition is a defining moment. It signals to investors exactly how management intends to use its capital to generate growth. Smithfield Foods (NASDAQ: SFD), which completed its Initial Public Offering (IPO) in Ja…READ THE FULL STORY
Tired of chasing the market every week? Our new free report reveals 10 U.S. stocks you can confidently buy now and hold long term — handpicked by a veteran investor with over 20 years of experience and backed by deep research into megatrends like AI, EVs, and cloud tech.CLICK HERE TO GET THE 10 STOCKS TO BUY AND HOLD — FREE FOR A LIMITED TIME
Many of the themes that pushed stocks higher in 2025 are back in focus to begin 2026. One of those is the bull market for precious metals. Many eyes are on silver, which has hit an all-time high. But investors shouldn’t sleep on gold, which shook off early-year weakness and reached a new all…READ THE FULL STORY
Abbott Laboratories’ (NYSE: ABT) January 2026 price pullback is making its stock look attractively valued. The move, driven more by market angst and fear than by any real weaknesses, seems to be a knee-jerk overreaction that has launched the stock back into the buy zone. The zone in question al…READ THE FULL STORY
Markets have been volatile lately, but dependable income opportunities still exist for investors who know where to look. We’re reviewing a small group of high-yield dividend stocks that continue to generate strong cash flow despite shifting conditions. Our latest guide outlines three companies operating in energy, consumer staples, and consumer finance, each producing billions in free cash flow and offering yields above typical market averages. These are established, cash-producing businesses built to reward shareholders through consistent payouts, not speculation. If steady income matters in today’s market, this breakdown is worth a closer look.ACCESS THE FREE DIVIDEND INCOME GUIDE AND REVIEW ALL THREE STOCKS TODAY
While the Magnificent Seven and massive technology conglomerates often dominate financial headlines, a quieter but equally significant shift is occurring in the small-cap sector. January 2026 has emerged as a critical month for a few specific companies valued under $2 billion. These firms are tran…READ THE FULL STORY
Shares of tech stock Atlassian Corp (NASDAQ: TEAM) are trading right around $130, after starting the year above $160. Considering the S&P 500 index is up more than 1% over that same timeframe, it’s been a pretty brutal start to the year for investors. It will perhaps, unfortunately, not hav…READ THE FULL STORY
The first month of the new year has put stocks on a roller coaster that reminds investors that volatility isn’t going away anytime soon. But gold and silver continue ignoring the noise and moving higher. In fact, at the close of markets on Jan. 22, the spot price of silver cracked the $95 ma…READ THE FULL STORY
If you’re searching for something on the internet and your web browser slows to a crawl, what’s the first thing you do? You hit the refresh button in hopes of speeding up the data and loading the website faster. It’s a similar concept to the one analysts at Piper Sandler believe …READ THE FULL STORY
Over the past year, airline stocks have trailed the broad market as the industry deals with elevated operating costs, economic uncertainty tamping down demand for flights, and pilot labor shortages. Complicating matters, the record-long government shutdown in the fall of 2025 adversely affected …READ THE FULL STORY
Gibraltar Industries, Inc. manufactures and provides products and services for the renewable energy, residential, agtech, and infrastructure markets in the United States and internationally. It operates through four segments: Renewables, Residential, Agtech, and Infrastructure. The Renewables segment designs, engineers, manufactures, and installs solar racking and electrical balance of systems for commercial and distributed generation scale solar installations. The Residential segment offers roo…VIEW TODAY’S STOCK PICK
The Early Bird is a daily email newsletter powered by MarketBeat that covers the top stories that will impact the stock market each day. Read your copy every morning at 7:00 AM Eastern so that you can “catch the worm” when the market opens.
RJ Hamster 